ArticleJournal of thoracic disease2026
C1ORF112 drives lung adenocarcinoma progression through e2f8-mediated transcriptional activation.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, with poor prognosis driven by metastasis and therapeutic resistance. Chromosome 1 open reading frame 112 (C1ORF112) encodes a nuclear protein involved in DNA replication and repair, but its role in LUAD is unclear. To systematically investigate the clinical relevance, functional impact, and transcriptional regulation of C1ORF112 in LUAD through integrative bioinformatic and experimental approaches. Methods: C1ORF112 expression and prognostic significance were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Single-cell RNA sequencing defined cellular localization and communication patterns. Functional enrichment, protein-protein interaction (PPI), and transcription factor prediction analyses were performed. In vitro assays and xenograft models assessed biological functions and transcriptional regulation by E2F8. Results: C1ORF112 was significantly upregulated in LUAD and correlated with poor overall survival (OS). Single-cell analysis showed elevated expression in malignant cells, fibroblasts, endothelial cells, and mast cells, accompanied by increased communication with M2 macrophages and exhausted CD8 Conclusions: Our integrative analysis suggests that C1ORF112 exhibits oncogenic properties in LUAD by promoting tumor survival, proliferation, and potentially remodeling the tumor microenvironment. The transcriptional activation by E2F8 highlights the E2F8-C1ORF112 axis as a candidate prognostic biomarker and therapeutic vulnerability, though prospective clinical validation and drug sensitivity studies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.